FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| A novel risk prediction nomogram for early death in patients with resected synchronous multiple primary colorectal cancer based on the SEER database. PMID 37191907 · Int J Colorectal Dis · 2023-May-16 The study is a retrospective, database-derived nomogram development and validation study. While it involves human oncology patients and includes chemotherapy as a factor, it is not a Phase II/III randomized controlled trial of a drug intervention with a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Protocol for the promoting resilience in stress management (PRISM) intervention: a multi-site randomized controlled trial for adolescents and young adults with advanced cancer. PMID 37189149 · BMC Palliat Care · 2023-May-16 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial. PMID 37137304 · Cell Rep Med · 2023-May-16 The record describes a randomized trial with a drug intervention and primary time-to-event endpoint (OS, HR) for an oncology condition, making it potentially eligible. However, the provided metadata (publication types, deterministic review) does not explicitly confirm Phase III, IIIb, or Phase II/III status; the phase is unclear. Furthermore, the abstract explicitly labels the results as an 'interim efficacy analysis,' classifying the report type as interim. Per the adjudication rules, a definitive phase must be explicitly established for eligibility, which is not the case here. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cognitive-behavioral rehabilitation in patients with cardiovascular diseases: a randomized controlled trial (CBR-CARDIO, DRKS00029295). PMID 37189029 · BMC Cardiovasc Disord · 2023-May-15 The study is a protocol for a randomized controlled trial in cardiovascular disease, not oncology. It evaluates a cognitive-behavioral rehabilitation program (a non-drug intervention) with a primary outcome of cardiac anxiety (a patient-reported outcome), not a time-to-event efficacy endpoint like OS or PFS. No results are presented. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study. PMID 37181228 · Innovation (Camb) · 2023-May-15 The trial meets criteria for oncology, human, randomized, phase III, and drug intervention, but the primary endpoint is overall response rate (ORR), which is not a time-to-event efficacy endpoint. No time-to-event outcomes (e.g., OS, PFS) or related analyses (Kaplan-Meier, HR) are mentioned in the abstract, so it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma. PMID 36999993 · Clin Cancer Res · 2023-May-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. PMID 36971777 · Clin Cancer Res · 2023-May-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer. PMID 36917691 · Clin Cancer Res · 2023-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial. PMID 37179362 · NPJ Breast Cancer · 2023-May-13 The record describes a biomarker analysis (TILs) predicting pathologic complete response and event-free survival within the SWOG S0800 trial, but it is not an original formal result report of a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS with Kaplan-Meier or HR). The phase (III) is mentioned in the title but the abstract does not confirm it as a Phase III trial; it only references randomization. The report is a secondary biomarker study, not the primary efficacy analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Risk factor analysis and nomogram establishment and verification of brain astrocytoma patients based on SEER database. PMID 37173353 · Sci Rep · 2023-May-12 The study is a retrospective, registry-based analysis (SEER database) to build a prognostic nomogram for brain astrocytoma. While it uses Kaplan-Meier and Cox regression, it is not a Phase II/III or Phase III randomized controlled trial testing a specific drug intervention. The publication type 'Randomized Controlled Trial' is likely a metadata error, as the abstract describes retrospective cohort analysis with random splitting for model training/validation, not a randomized trial of an intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical study of rhGM-CSF for the treatment of pulmonary exogenous acute respiratory distress syndrome by modulating alveolar macrophage subtypes: A randomized controlled trial. PMID 37171348 · Medicine (Baltimore) · 2023-May-12 The study is a randomized controlled trial of rhGM-CSF in patients with acute respiratory distress syndrome (ARDS), which is not a malignant neoplasm. The primary endpoints are physiological and inflammatory markers, not time-to-event efficacy endpoints like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Salvage radiotherapy after radical prostatectomy: functional outcomes in the LAPPRO trial after 8-year follow-up. PMID 37170656 · Scand J Urol · 2023-May-11 The study is a non-randomized, prospective controlled trial evaluating the long-term functional outcomes and side-effects of salvage radiotherapy (a non-drug intervention) after radical prostatectomy for prostate cancer. It does not meet the eligibility criteria: it is not randomized, does not involve a drug intervention, and does not have a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications and improve quality of life in colorectal cancer surgery. PMID 37162250 · Cochrane Database Syst Rev · 2023-May-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia. PMID 36763945 · J Clin Oncol · 2023-May-10 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors. PMID 37158938 · J Hematol Oncol · 2023-May-08 This is a Phase I/Ib study reporting safety, PK/PD, and preliminary efficacy (primarily ORR). It is not a randomized controlled trial, not Phase III/IIIb, and does not report a primary time-to-event efficacy endpoint like OS or PFS with Kaplan-Meier analysis or HR. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Detection of colon cancer recurrences during follow-up care by general practitioners vs surgeons. PMID 36715623 · J Natl Cancer Inst · 2023-May-08 The study is a randomized trial with a time-to-event endpoint in oncology, but it does not meet the core eligibility criteria because the intervention is not drug-containing, and the trial phase is not confirmed as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The influence of shunting left/right portal vein branch on post-TIPS hepatic encephalopathy: a study protocol for multicenter randomized blinded controlled trial. PMID 37149647 · Trials · 2023-May-06 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis. PMID 37205426 · medRxiv · 2023-May-05 This is a Mendelian randomization study investigating the association between genetic proxies for inflammatory markers and cancer risk. It is not a randomized controlled trial of a drug intervention with a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of long-term quality of life between Billroth-I and Roux-en-Y anastomosis after distal gastrectomy for gastric cancer: a randomized controlled trial. PMID 37014767 · Chin Med J (Engl) · 2023-May-05 The study is a randomized controlled trial in oncology (gastric cancer) with time-to-event efficacy endpoints (overall survival, recurrence-free survival). However, it compares two surgical reconstruction techniques (Billroth-I vs. Roux-en-Y) after gastrectomy; there is no drug-containing intervention. Therefore, it does not meet the criteria for inclusion in the drug-intervention-focused cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Leveraging social media to increase lung cancer screening awareness, knowledge and uptake among high-risk populations (The INSPIRE-Lung Study): Study protocol of design and methods of a community-based randomized controlled trial. PMID 37205569 · Res Sq · 2023-May-04 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. PMID 37146227 · Cochrane Database Syst Rev · 2023-May-04 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Stereotactic Body radiotherapy and pedicLE screw fixatioN During one hospital visit for patients with symptomatic unstable spinal metastases: a randomized trial (BLEND RCT) using the Trials within Cohorts (TwiCs) design. PMID 37143158 · Trials · 2023-May-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. PMID 36796016 · Blood · 2023-May-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Allograft Versus Bioactive Glass (BG-S53P4) in Pediatric Benign Bone Lesions: A Randomized Clinical Trial. PMID 36727973 · J Bone Joint Surg Am · 2023-May-03 The study is a randomized clinical trial with results, but it is not an oncology study (benign pediatric bone lesions), does not involve a drug intervention, and does not have a time-to-event efficacy endpoint. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study). PMID 37130682 · BMJ Open · 2023-May-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Drainless robot-assisted minimally invasive oesophagectomy-randomized controlled trial (RESPECT). PMID 37127683 · Trials · 2023-May-02 The record is a protocol for a randomized trial on surgical drain management in oesophageal cancer surgery. It lacks results and does not report a time-to-event endpoint (like OS/PFS) or a drug intervention. It is therefore excluded. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effect of Perioperative Palliative Care on Health-Related Quality of Life Among Patients Undergoing Surgery for Cancer: A Randomized Clinical Trial. PMID 37256623 · JAMA Netw Open · 2023-May-01 The study is a randomized trial in surgical oncology patients, but it evaluates a palliative care intervention (non-drug) and measures patient-reported outcomes (quality of life, distress), not a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the inclusion criteria for a drug-containing intervention with a time-to-event primary/key secondary endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials. PMID 37195664 · JAMA Netw Open · 2023-May-01 The record is a meta-research cross-sectional study assessing changes in primary endpoints across many oncology RCTs. It does not present original results, including time-to-event efficacy data or hazard ratios, for a single drug-containing randomized trial. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Analysis of Body Mass Index in Early and Middle Adulthood and Estimated Risk of Gastrointestinal Cancer. PMID 37163267 · JAMA Netw Open · 2023-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. PMID 37126944 · J Clin Oncol · 2023-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial. PMID 37071498 · Clin Cancer Res · 2023-May-01 The report is from a randomized oncology trial with a time-to-event endpoint (IBTR as a recurrence) and is an original result. However, it is not eligible because: 1) The trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata (the deterministic review noted phase evidence is unclear and not confirmed). 2) The intervention is not a drug-containing intervention; it compares adjuvant radiotherapy vs. no radiotherapy, which is a non-drug-only intervention. The criteria require a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial. PMID 37070950 · Hepatology · 2023-May-01 The record describes a randomized, controlled trial with a drug intervention and a primary time-to-event efficacy endpoint (DFS). However, the trial phase is not explicitly stated in the provided title, abstract, metadata, or deterministic review to be Phase III/IIIb or Phase II/III. The deterministic review indicates phase evidence is unclear. Without explicit confirmation of Phase III/IIIb or Phase II/III status, the record cannot be deemed eligible under the adjudication criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The comparison of efficacy and safety evaluation of vacuum-assisted Elite 10-G system and the traditional BARD 14-G core needle in breast diagnosis: an open-label, parallel, randomized controlled trial. PMID 37042316 · Int J Surg · 2023-May-01 The study is a randomized, phase III trial with original results, but it compares two diagnostic biopsy devices (vacuum-assisted vs. core needle) for breast lesion diagnosis. It does not involve a drug-containing intervention and its primary endpoints are diagnostic accuracy and safety, not time-to-event efficacy outcomes (OS, PFS, DFS, etc.) or time-to-event analysis methods (Kaplan-Meier, HR). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial. PMID 37038986 · Int J Surg · 2023-May-01 The record describes a randomized, multicenter trial with a time-to-event primary endpoint (OS) and a drug-containing intervention (sorafenib). However, the trial phase is not explicitly stated in the title, abstract, or metadata as Phase III/IIIb or Phase II/III. The 'phase3_or_definitive' criterion cannot be established from the provided information, so the study is not eligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Outcomes After Endovascular Therapy With Procedural Sedation vs General Anesthesia in Patients With Acute Ischemic Stroke: The AMETIS Randomized Clinical Trial. PMID 37010829 · JAMA Neurol · 2023-May-01 The record describes a randomized trial in acute ischemic stroke, not oncology. The interventions are anesthesia strategies (general vs. procedural sedation) for thrombectomy, not drug therapies. The primary endpoint is a composite of functional independence and complication rates at specific timepoints, not a time-to-event outcome like OS, PFS, or DFS with Kaplan-Meier analysis or HR. Therefore, it fails multiple eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial. PMID 36951834 · JAMA Oncol · 2023-May-01 The record describes a randomized, open-label, phase 2b clinical trial with a drug-containing intervention and a primary time-to-event endpoint (PFS). It reports original updated efficacy results. However, the phase is explicitly stated as 'phase 2b,' which does not meet the eligibility criterion requiring Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial. PMID 36928279 · JAMA Oncol · 2023-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Five-Year Survival Outcomes of Laparoscopy-Assisted vs Open Distal Gastrectomy for Advanced Gastric Cancer: The JLSSG0901 Randomized Clinical Trial. PMID 36920382 · JAMA Surg · 2023-May-01 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
B
|
仅广召回影子组 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial. PMID 36892833 · JAMA Oncol · 2023-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma. PMID 36892581 · Clin Cancer Res · 2023-May-01 The study is a randomized, placebo-controlled trial of a MUC1 peptide vaccine in humans with colorectal adenoma. However, the primary endpoint is immunogenicity (a proportion at 12 weeks). The clinical efficacy endpoint is adenoma recurrence measured as a relative risk at ≥1 year, not a time-to-event outcome like OS, PFS, DFS, etc., with no mention of Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the requirement for a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19. PMID 36870577 · Eur J Pharm Sci · 2023-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415. PMID 36736921 · Int J Radiat Oncol Biol Phys · 2023-May-01 The record is an original, randomized, oncology trial with a time-to-event endpoint, but it does not meet the core eligibility criterion of a drug-containing intervention. The intervention is radiation therapy, which is non-drug. Additionally, the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided abstract or metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial. PMID 36729404 · Invest Radiol · 2023-May-01 The record is excluded because it is not a therapeutic oncology trial. While it is a randomized phase III trial in humans, it evaluates a diagnostic contrast agent (gadopiclenol) for MRI, not a therapeutic drug for cancer treatment. Furthermore, the primary and key secondary endpoints are diagnostic imaging parameters and adverse events, not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP) or survival analyses (Kaplan-Meier, HR). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Socioeconomic Barriers to Randomized Clinical Trial Retention in Patients Treated With Adjuvant Radiation for Early-Stage Breast Cancer. PMID 36724858 · Int J Radiat Oncol Biol Phys · 2023-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer. PMID 36716292 · Clin Cancer Res · 2023-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. PMID 36469000 · Clin Cancer Res · 2023-May-01 Meets all criteria: oncology, human, randomized, definitive trial phase (VISION), drug intervention, primary time-to-event efficacy endpoint (OS with HR), and original result report. No exclusions apply. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 1 Figure · 1 Panel · risk visible |
| Surgery for glioblastomas in the elderly: an Association des Neuro-oncologues d'Expression Française (ANOCEF) trial. PMID 36242578 · J Neurosurg · 2023-May-01 The trial is a randomized oncology study in humans with a time-to-event endpoint (OS, PFS) and includes a drug (temozolomide) as standard adjunct therapy. However, the primary intervention is surgical (resection vs. biopsy), not a drug comparison. Additionally, the trial phase is not explicitly defined as Phase III or definitive in the provided metadata, and the criteria require an explicit drug-containing intervention as the primary comparison. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparing efficacy and safety of stair step protocols for clomiphene citrate and letrozole in ovulation induction for women with polycystic ovary syndrome (PCOS): a randomized controlled clinical trial. PMID 37520487 · J Med Life · 2023-May 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of Erector Spinae Block and Pectoralis Block on Quality of Recovery and Analgesia After Modified Radical Mastectomy: A randomised controlled study. PMID 37377822 · Sultan Qaboos Univ Med J · 2023-May The study is a randomized controlled trial in human oncology patients (breast cancer surgery), but it is ineligible because it evaluates anesthetic/analgesic nerve blocks, not a systemic drug intervention, and uses a quality-of-recovery score as the primary endpoint, not a time-to-event efficacy endpoint. The trial phase is also not established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF. PMID 37309702 · Future Oncol · 2023-May Abstract explicitly reports a randomized Phase III oncology trial with drug interventions and a time-to-event efficacy endpoint (progression-free survival, PFS), meeting all inclusion criteria for a 5-year updated result. |
H
L
B
|
旧查询独有 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |